Equecabtagene autoleucel is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Equecabtagene autoleucel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Equecabtagene autoleucel overview
Equecabtagene autoleucel (Fucaso) is an autologous BCMA CAR-T cell immunotherapy drug. It is formulated as solution for intravenous route of adminstration. Fucaso is used to treat adult patients with relapsed or refractory multiple myeloma who have progressed after at least 3 lines of therapy (at least one proteasome inhibitor and immunomodulator).
See Also:
Equecabtagene autoleucel (CT-103A) is under development for the treatment of neuromyelitis optica spectrum disorder (NMOSD), relapsed and refractory antibody-associated idiopathic inflammatory diseases of the nervous system, immune-mediated necrotizing myopathy, multiple myeloma, MGUS (Monoclonal gammopathy of undetermined significance), and POEMS syndrome. The therapeutic candidate comprises a lentiviral vector containing a CAR structure with a fully human scFv, CD8a hinger and transmembrane, 4-1BB co-stimulatory and CD3z activation domains.. It is administered through parenteral/intravenous route.
Nanjing IASO Biotherapeutics overview
Nanjing IASO Biotherapeutics is a biopharmaceutical company that develops and manufactures tumor cell immunotherapy and antibody drugs. The company is headquartered in Nanjing, Jiangsu, China.
For a complete picture of Equecabtagene autoleucel’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.